Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depakote in adolescents with bipolar disorder
NCT00271258Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of divalproex sodium in bipolar disorder (BD), sponsored by Sanofi. Primary endpoint: Clinical and physiological tolerance at 6 months. Started Jan 2005; status: completed.
02
Drugs
divalproex sodium
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00271258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271258.